
================================================================================
          PAN-CANCER X-NODE TARGET DISCOVERY - LAB PROTOCOLS
================================================================================
Generated: 2026-02-01
Method: High-throughput systems biology (DepMap + Network Analysis)
Reference: Based on PDAC X-node methodology (targeted combination therapy)

================================================================================
PRIORITY COMBINATIONS FOR IN VIVO TESTING
================================================================================

--------------------------------------------------------------------------------
PROTOCOL 1: Ovarian Germ Cell Tumor
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: KRAS
  • Target 2: MET  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: sotorasib
  • Drug 2: capmatinib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.35 (lower = better)
  • Path Coverage: 100.0%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 2: Anaplastic Thyroid Cancer
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: BRAF
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: vemurafenib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.39 (lower = better)
  • Path Coverage: 84.6%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 2 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 3: Ampullary Carcinoma
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: EGFR
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: erlotinib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.39 (lower = better)
  • Path Coverage: 100.0%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 4: Mucosal Melanoma of the Vulva/Vagina
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: BRAF
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: vemurafenib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.39 (lower = better)
  • Path Coverage: 100.0%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 2 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 5: Hepatoblastoma
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: BRAF
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: vemurafenib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.39 (lower = better)
  • Path Coverage: 85.7%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 2 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 6: Lung Neuroendocrine Tumor
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: CDK2
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: dinaciclib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.44 (lower = better)
  • Path Coverage: 96.9%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 7: Ovarian Epithelial Tumor
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: CDK2
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: dinaciclib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.44 (lower = better)
  • Path Coverage: 92.2%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 8: Endometrial Carcinoma
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: CDK2
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: dinaciclib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.44 (lower = better)
  • Path Coverage: 97.1%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 9: Cervical Squamous Cell Carcinoma
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: CDK2
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: dinaciclib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.44 (lower = better)
  • Path Coverage: 88.2%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


--------------------------------------------------------------------------------
PROTOCOL 10: Merkel Cell Carcinoma
--------------------------------------------------------------------------------
TARGET COMBINATION:
  • Target 1: CDK2
  • Target 2: KRAS  
  • Target 3: STAT3

DRUG PROTOCOL:
  • Drug 1: dinaciclib
  • Drug 2: sotorasib
  • Drug 3: napabucasin

COMPUTATIONAL METRICS:
  • Synergy Score: 0.92 (higher = better)
  • Resistance Score: 0.44 (lower = better)
  • Path Coverage: 100.0%
  • Literature Validation: 0.56 (low = NOVEL)

RATIONALE:
  This triple combination targets 3 cancer pathways
  with predicted high synergy and low resistance probability.
  All 3 targets have approved/clinical-stage drugs available.


================================================================================
SUGGESTED EXPERIMENTAL DESIGN
================================================================================
1. Cell Lines: Use DepMap-validated lines for each cancer type
2. In Vitro: Test single, double, and triple combinations
3. Synergy Analysis: Calculate Bliss/Loewe synergy scores
4. In Vivo: Xenograft models with combination dosing
5. Endpoints: Tumor volume, survival, resistance emergence

================================================================================
